Clinical and immunological features associated to the development of a sustained immune humoral response in COVID-19 patients: Results from a cohort study.

Autor:	Torres-Ruiz J; Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico., Lomelín-Gascón J; Operative Solutions, Carlos Slim Foundation, Mexico City, Mexico., Vargas-Castro AS; Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico., Lira-Luna J; Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.; Sección de Estudios de Posgrado e Investigación, Escuela Superior de Medicina-Instituto Politécnico Nacional (IPN), Mexico City, Mexico., Pérez-Fragoso A; Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.; Laboratorio de Inmunoquimica 1, Posgrado en Ciencias Químicobiológicas, Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional, Mexico City, Mexico., Tapia-Conyer R; Operative Solutions, Carlos Slim Foundation, Mexico City, Mexico.; Universidad Nacional Autónoma de México, Facultad de Medicina, Mexico City, Mexico., Nuñez-Aguirre M; Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.; Laboratorio de Inmunoquimica 1, Posgrado en Ciencias Químicobiológicas, Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional, Mexico City, Mexico., Alcalá-Carmona B; Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.; Laboratorio de Inmunoquimica 1, Posgrado en Ciencias Químicobiológicas, Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional, Mexico City, Mexico., Absalón-Aguilar A; Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.; Internal Medicine Department, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico., Maravillas-Montero JL; Red de Apoyo a la Investigación, Universidad Nacional Autónoma de México e Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico., Mejía-Domínguez NR; Red de Apoyo a la Investigación, Universidad Nacional Autónoma de México e Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico., Núñez-Álvarez C; Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico., Rull-Gabayet M; Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico., Llorente L; Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico., Romero-Ramírez S; Red de Apoyo a la Investigación, Universidad Nacional Autónoma de México e Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico., Sosa-Hernández VA; Red de Apoyo a la Investigación, Universidad Nacional Autónoma de México e Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico., Cervantes-Díaz R; Red de Apoyo a la Investigación, Universidad Nacional Autónoma de México e Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico., Juárez-Vega G; Red de Apoyo a la Investigación, Universidad Nacional Autónoma de México e Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico., Meza-Sánchez DE; Red de Apoyo a la Investigación, Universidad Nacional Autónoma de México e Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico., Martínez-Juárez LA; Operative Solutions, Carlos Slim Foundation, Mexico City, Mexico.; Clinical Research, London School of Hygiene and Tropical Medicine, London, United Kingdom., Morales-Juárez L; Operative Solutions, Carlos Slim Foundation, Mexico City, Mexico.; Temporary COVID-19 Hospital, Hipódromo de las Américas, Mexico City, Mexico., López-López LN; Operative Solutions, Carlos Slim Foundation, Mexico City, Mexico., Negrete-Trujillo JA; Operative Solutions, Carlos Slim Foundation, Mexico City, Mexico., Falcón-Lezama JA; Operative Solutions, Carlos Slim Foundation, Mexico City, Mexico.; Division of Health Sciences, Juárez Autonomous University of Tabasco, Tabasco, Mexico., Valdez-Vázquez RR; Temporary COVID-19 Hospital, Hipódromo de las Américas, Mexico City, Mexico., Gallardo-Rincón H; Centro Universitario de Ciencias de la Salud (CUCS), Universidad de Guadalajara, Guadalajara, Mexico., Gómez-Martín D; Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.
Jazyk:	angličtina
Zdroj:	Frontiers in immunology [Front Immunol] 2022 Aug 15; Vol. 13, pp. 943563. Date of Electronic Publication: 2022 Aug 15 (Print Publication: 2022).
DOI:	10.3389/fimmu.2022.943563
Abstrakt:	Background: Until now, most of the research addressing long-term humoral responses in coronavirus disease 2019 (COVID-19) had only evaluated the serum titers of anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) IgGs, without the assessment of the baseline antiviral clinical and immune profile, which is the aim of this study and may be the key factor leading to a broad and sustained antibody response. Methods: We included 103 patients with COVID-19. When the patients sought medical attention (baseline), a blood sample was drawn to perform immunophenotype of lymphocytes by flow cytometry. The patients were assessed 15 days after baseline and then every month until the third month, followed by a last visit 6 months after recruitment. We evaluated the anti-SARS-COV-2 IgG at all time points, and the serum levels of cytokines, chemokines, anti-cellular (AC) antibodies and neutrophil extracellular traps were also assessed during the follow-up. The primary outcome of the study was the presence of a sustained immune humoral response, defined as an anti-SARS-CoV-2 IgG titer >4.99 arbitrary units/mL in at least two consecutive measures. We used generalized lineal models to assess the features associated with this outcome and to assess the effect of the changes in the cytokines and chemokines throughout time on the development of a sustained humoral immune response. Results: At baseline the features associated to a sustained immune humoral response were the diagnosis of critical disease, absolute number of lymphocytes, serum IP-10, IL-4, IL-2, regulatory T cells, CD8 + T cells, and positive AC antibodies. Critical illness and the positivity of AC antibodies were associated with a sustained humoral immune response after 3 months, whilst critical illness and serum IL-13 were the explanatory variables after 6 months. Conclusion: A sustained immune humoral response is strongly related to critical COVID-19, which is characterized by the presence of AC antibodies, quantitative abnormalities in the T cell compartment, and the serum cytokines and chemokines during acute infection and throughout time. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2022 Torres-Ruiz, Lomelín-Gascón, Vargas-Castro, Lira-Luna, Pérez-Fragoso, Tapia-Conyer, Nuñez-Aguirre, Alcalá-Carmona, Absalón-Aguilar, Maravillas-Montero, Mejía-Domínguez, Núñez-Álvarez, Rull-Gabayet, Llorente, Romero-Ramírez, Sosa-Hernández, Cervantes-Díaz, Juárez-Vega, Meza-Sánchez, Martínez-Juárez, Morales-Juárez, López-López, Negrete-Trujillo, Falcón-Lezama, Valdez-Vázquez, Gallardo-Rincón and Gómez-Martín.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu